Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis

Summary

This study is a single-center, single-arm, open-label, exploratory clinical trial. A total of 30 patients with diffuse cutaneous systemic sclerosis (dcSSc) will be enrolled. A historical control cohort will be established to evaluate the efficacy and safety of Firsekibart by comparing with historical data.

Timeline

Start

2026-05-01

Primary completion

2027-04-01

Completion

2028-12-01

Drugs

Indications